223 related articles for article (PubMed ID: 16757974)
1. Long-term follow-up of myeloablative allogeneic stem cell transplantation using Campath "in the bag" as T-cell depletion: the Leiden experience.
Barge RM; Starrenburg CW; Falkenburg JH; Fibbe WE; Marijt EW; Willemze R
Bone Marrow Transplant; 2006 Jun; 37(12):1129-34. PubMed ID: 16757974
[TBL] [Abstract][Full Text] [Related]
2. A study of a reduced-intensity conditioning regimen followed by allogeneic stem cell transplantation for patients with hematologic malignancies using Campath-1H as part of a graft-versus-host disease strategy.
Shore T; Harpel J; Schuster MW; Roboz GJ; Leonard JP; Coleman M; Feldman EJ; Silver RT
Biol Blood Marrow Transplant; 2006 Aug; 12(8):868-75. PubMed ID: 16864057
[TBL] [Abstract][Full Text] [Related]
3. The effect of in vivo T cell depletion with alemtuzumab on reduced-intensity allogeneic hematopoietic cell transplantation for chronic lymphocytic leukemia.
Delgado J; Pillai S; Benjamin R; Caballero D; Martino R; Nathwani A; Lovell R; Thomson K; Perez-Simon JA; Sureda A; Kottaridis P; Vazquez L; Peggs K; Sierra J; Milligan D; Mackinnon S
Biol Blood Marrow Transplant; 2008 Nov; 14(11):1288-97. PubMed ID: 18940684
[TBL] [Abstract][Full Text] [Related]
4. Reduced-intensity conditioning allogeneic stem cell transplantation with donor T-cell depletion using alemtuzumab added to the graft ('Campath in the bag').
von dem Borne PA; Starrenburg CW; Halkes SJ; Marijt WA; Fibbe WE; Falkenburg JH; Willemze R
Curr Opin Oncol; 2009 Jun; 21 Suppl 1():S27-9. PubMed ID: 19561408
[TBL] [Abstract][Full Text] [Related]
5. Prevention of graft vs. host disease with alemtuzumab 'in the bag' decreases early toxicity of stem cell transplantation and in multiple myeloma is associated with improved long-term outcome.
Novitzky N; Thomas V; du Toit C
Cytotherapy; 2008; 10(1):45-53. PubMed ID: 18202974
[TBL] [Abstract][Full Text] [Related]
6. CD52 antibodies for prevention of graft-versus-host disease and graft rejection following transplantation of allogeneic peripheral blood stem cells.
Hale G; Jacobs P; Wood L; Fibbe WE; Barge R; Novitzky N; Toit C; Abrahams L; Thomas V; Bunjes D; Duncker C; Wiesneth M; Selleslag D; Hidajat M; Starobinski M; Bird P; Waldmann H
Bone Marrow Transplant; 2000 Jul; 26(1):69-76. PubMed ID: 10918407
[TBL] [Abstract][Full Text] [Related]
7. Reduced-intensity conditioning containing low-dose alemtuzumab before allogeneic peripheral blood stem cell transplantation: graft-versus-host disease is decreased but T-cell reconstitution is delayed.
Dodero A; Carrabba M; Milani R; Rizzo E; Raganato A; Montefusco V; Farina L; Milanesi M; Longoni P; Carlo-Stella C; Corradini P
Exp Hematol; 2005 Aug; 33(8):920-7. PubMed ID: 16038785
[TBL] [Abstract][Full Text] [Related]
8. Long-term outcome of myeloablative allogeneic stem cell transplantation for multiple myeloma.
Kuruvilla J; Shepherd JD; Sutherland HJ; Nevill TJ; Nitta J; Le A; Forrest DL; Hogge DE; Lavoie JC; Nantel SH; Toze CL; Smith CA; Barnett MJ; Song KW
Biol Blood Marrow Transplant; 2007 Aug; 13(8):925-31. PubMed ID: 17640596
[TBL] [Abstract][Full Text] [Related]
9. Polyoma viruria following T-cell-depleted allogeneic transplants using Campath-1H: incidence and outcome in relation to graft manipulation, donor type and conditioning.
Chakrabarti S; Osman H; Collingham K; Milligan DW
Bone Marrow Transplant; 2003 Mar; 31(5):379-86. PubMed ID: 12634729
[TBL] [Abstract][Full Text] [Related]
10. Low-dose alemtuzumab vs. standard policy for prevention of graft-versus-host disease in unrelated and related allogeneic stem cell transplantation-a matched pair analysis.
Busemann C; Neumann T; Schulze M; Klenner A; Thiele T; Greinacher A; Dölken G; Krüger WH
Ann Hematol; 2013 Jul; 92(7):945-52. PubMed ID: 23463451
[TBL] [Abstract][Full Text] [Related]
11. Campath-1 Abs 'in the bag' for hematological malignancies: the Cape Town experience.
Novitzky N; Thomas V; Hale G; Waldmann H
Cytotherapy; 2004; 6(2):172-81. PubMed ID: 15203994
[TBL] [Abstract][Full Text] [Related]
12. Successful treatment of stem cell graft failure in pediatric patients using a submyeloablative regimen of campath-1H and fludarabine.
Ahmed N; Leung KS; Rosenblatt H; Bollard CM; Gottschalk S; Myers GD; Carrum G; Heslop HE; Brenner MK; Krance RA
Biol Blood Marrow Transplant; 2008 Nov; 14(11):1298-304. PubMed ID: 18940685
[TBL] [Abstract][Full Text] [Related]
13. Influence of cytomegalovirus (CMV) sero-positivity on CMV infection, lymphocyte recovery and non-CMV infections following T-cell-depleted allogeneic stem cell transplantation: a comparison between two T-cell depletion regimens.
Chakrabarti S; Milligan DW; Brown J; Osman H; Vipond IB; Pamphilon DH; Marks DI
Bone Marrow Transplant; 2004 Jan; 33(2):197-204. PubMed ID: 14647256
[TBL] [Abstract][Full Text] [Related]
14. Treatment-related mortality and graft-versus-leukemia activity after allogeneic stem cell transplantation for chronic lymphocytic leukemia using intensity-reduced conditioning.
Dreger P; Brand R; Hansz J; Milligan D; Corradini P; Finke J; Deliliers GL; Martino R; Russell N; Van Biezen A; Michallet M; Niederwieser D;
Leukemia; 2003 May; 17(5):841-8. PubMed ID: 12750695
[TBL] [Abstract][Full Text] [Related]
15. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
16. Pretransplant conditioning with Campath-1H (alemtuzumab) in pediatric matched unrelated hematopoietic stem cell transplants: an institutional experience.
Nageswara Rao AA; Kumar R; Altaf S; Gourde JA; Rodriguez V; Khan SP
J Pediatr Hematol Oncol; 2012 Mar; 34(2):96-100. PubMed ID: 22146532
[TBL] [Abstract][Full Text] [Related]
17. Low-dose alemtuzumab (Campath) in myeloablative allogeneic stem cell transplantation for CD52-positive malignancies: decreased incidence of acute graft-versus-host-disease with unique pharmacokinetics.
Khouri IF; Albitar M; Saliba RM; Ippoliti C; Ma YC; Keating MJ; Champlin RE
Bone Marrow Transplant; 2004 Apr; 33(8):833-7. PubMed ID: 14755312
[TBL] [Abstract][Full Text] [Related]
18. Cytomegalovirus (CMV) infections and CMV-specific cellular immune reconstitution following reduced intensity conditioning allogeneic stem cell transplantation with Alemtuzumab.
Lamba R; Carrum G; Myers GD; Bollard CM; Krance RA; Heslop HE; Brenner MK; Popat U
Bone Marrow Transplant; 2005 Nov; 36(9):797-802. PubMed ID: 16151431
[TBL] [Abstract][Full Text] [Related]
19. A pilot phase II study of alternate day ganciclovir and foscarnet in preventing cytomegalovirus (CMV) infections in at-risk pediatric and adolescent allogeneic stem cell transplant recipients.
Shereck EB; Cooney E; van de Ven C; Della-Lotta P; Cairo MS
Pediatr Blood Cancer; 2007 Sep; 49(3):306-12. PubMed ID: 16972242
[TBL] [Abstract][Full Text] [Related]
20. In stem cell transplantation, by limiting the morbidity of graft-versus-host disease tolerance to myeloablative conditioning is improved.
Novitzky N; Thomas V; du Toit C; Mcdonald A
Biol Blood Marrow Transplant; 2008 Jun; 14(6):709-18. PubMed ID: 18489997
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
